Summary of Key Points Core Viewpoint - The pharmaceutical industry is experiencing a slowdown in revenue growth but is improving in quality and profitability, with a notable increase in innovation and financing activities [2][3]. Group 1: Healthcare Fund and Expenditure - The cumulative income growth of the healthcare insurance fund for 2025 was +3.6%, with urban employee and rural resident contributions growing by +5.5% and +0.8% respectively [5]. - The cumulative expenditure growth of the healthcare insurance fund was +1.7%, with urban employee and rural resident expenditures increasing by +2.8% and +0.4% respectively [6]. - The total expenditure in the healthcare sector for December 2025 was 275.9 billion yuan, reflecting a +12.1% year-on-year increase, with total annual expenditure reaching 2,144.6 billion yuan (+5.7%) [7]. Group 2: Pharmaceutical Manufacturing - The industrial added value of the pharmaceutical manufacturing sector showed a cumulative growth of +2.4% for 2025, with December's growth at +7.0%, surpassing the national industrial growth rate [9]. - The total revenue and profit for the pharmaceutical industry in 2025 were 24,870 billion yuan (-1.7%) and 349 billion yuan (+2.0%) respectively, with a profit margin of 14.0% (+0.5 percentage points) [9]. Group 3: Hospital and Retail Market - The total number of hospital diagnoses in major cities showed improvement in the second half of 2025 compared to the first half, with a slight decrease in discharge numbers [14][19]. - The retail sales of traditional Chinese and Western medicines grew by +1.8% in 2025, indicating a mild recovery trend, although some categories like health products faced significant declines [21]. Group 4: Export and Import Trends - The export of high-value medical devices such as endoscopes and CT machines saw significant growth, with increases of +31.9% and +7.6% respectively in 2025 [27]. - The import of medical devices showed a downward trend, with certain categories like MRI and ultrasound equipment experiencing declines, while CT imports increased by +22.5% [45]. Group 5: Innovation and Financing - A total of 70 new chemical and biological drugs were approved in 2025, a significant increase from 48 in 2024, indicating a robust innovation environment [60]. - The financing amount in the domestic healthcare sector reached 122.8 billion yuan (+46.41%) in 2025, with a notable recovery in IPO activities, which saw a +273% increase in financing amount [65].

北交所新股申购报告 海圣医疗（920166.BJ）：麻醉监护医疗器械小巨人，麻醉监护精准化矩阵驱动成长 北交所研究团队 ——北交所新股申购报告 | 诸海滨（分析师） | 车欣航（分析师） | | --- | --- | | zhuhaibin@kysec.cn | chexinhang@kysec.cn | | 证书编号：S0790522080007 | 证书编号：S0790525050001 | 海圣医疗：麻醉、监护类医疗器械细分领域国家级专精特新"小巨人" 海圣医疗是面向全球的麻醉、监护类医疗器械综合产品提供商，为国内该细分领 域头部企业，获评国家级专精特新"小巨人"、浙江省隐形冠军企业等。公司产 品广泛应用于麻醉科、ICU、急诊科等临床科室。技术研发上，截至 2025 年 6 月 30 日，公司已先后承担国家、省、市级重大科技项目十余项，已累计获国家 授权专利 63 项，其中发明专利 13 项。经营层面，2024 年公司营收 3.04 亿元， 同比微降 0.70%，归母净利润 7091.75 万元；2025 年前三季度营收、归母净利润 同比分别增长 19.89%、26.70%，增长态势向好。2024 年 ...

Core Viewpoint - The domestic AI-assisted medical technology is advancing, with significant developments in the approval of innovative medical devices and the application of AI in healthcare, indicating a potential for rapid growth in the AI+ healthcare market [1][2]. Group 1: Market Performance - As of February 3, 2026, the CSI Medical and Medical Device Innovation Index (931484) increased by 0.57%, with notable gains from stocks such as Aimeike (+4.07%), Jianfan Bio (+2.36%), and Xinhengcheng (+2.29%) [1]. - The Medical Innovation ETF (516820) also rose by 0.57%, with the latest price reported at 0.36 yuan [1]. Group 2: AI in Healthcare - AI applications in smart healthcare are becoming mature, particularly in medical imaging diagnostics, where AI assists doctors in improving interpretation efficiency [2]. - Recent AI medical products have accelerated their market entry, including the "Cervical Cell Digital Pathology Image Auxiliary Diagnosis Software" approved in January 2026 and the "Yuan Zhi" model from United Imaging, which achieved over 95% accuracy in complex lesion diagnosis [2]. - The combination of technological iteration and policy support is expected to drive rapid growth in the domestic AI+ healthcare market [2]. Group 3: Index Composition - The CSI Medical and Medical Device Innovation Index comprises 30 publicly listed companies with strong profitability, growth potential, and R&D innovation capabilities, reflecting the overall performance of profitable and growth-oriented medical and medical device companies [2]. - As of January 30, 2026, the top ten weighted stocks in the index include WuXi AppTec, Mindray Medical, and Hengrui Medicine, collectively accounting for 63.9% of the index [2].

Core Viewpoint - WanDong Medical is expected to report a significant net loss for 2025, transitioning from a profitable state to a phase of pressure on earnings [1][3]. Performance Overview - The company forecasts a net profit attributable to shareholders of between -199 million to -257 million yuan for 2025. - The net profit after deducting non-recurring items is expected to be between -213 million to -271 million yuan. - In contrast, the company achieved a net profit of 157 million yuan in 2024, with a net profit of 142 million yuan after deducting non-recurring items, indicating a clear reversal in performance for 2025 [3]. Reasons for Performance Pressure - The decline in performance for 2025 is attributed to three main factors: 1. The impact of centralized procurement and price adjustments on gross profit margins. The company is participating in centralized procurement for medical equipment, adopting more competitive pricing strategies to increase bid success rates, which compresses product gross margins and affects current profits [4]. 2. Increased R&D investment leading to short-term cost pressures. The company is intensifying R&D in high-end medical imaging equipment, focusing on CT, MR, and DSA products, which results in a temporary drag on profits due to increased R&D expenditures [5]. 3. Rising costs associated with expanding into overseas and high-tier hospital markets. The company is advancing its overseas market layout and enhancing its marketing and organizational investments in domestic high-tier hospitals, leading to increased costs [6]. Industry Perspective - The expected loss for WanDong Medical in 2025 is seen as a typical case of "transitional pressure" in the imaging equipment industry amid centralized procurement and structural upgrades. - High-end imaging equipment is gradually being included in more price-constrained procurement systems, making it difficult for domestic manufacturers to avoid temporary declines in gross margins, even with increased bid volumes. - The shift towards high-end, systematic, and overseas operations inherently requires longer cycles, higher R&D intensity, and heavier organizational investments. - The company has not retreated from its strategic goals but has chosen a path of "exchanging scale for time and investment for technological reserves" in the centralized procurement environment. This strategy may be unfavorable for profits in the short term but is worth observing from a medium to long-term perspective, especially in core areas like CT, MR, and DSA where domestic replacement is deepening [7]. Key Variables for the Future - The future performance will depend on the commercialization pace of high-end imaging products, the efficiency of overseas market order conversions, and the ability to rebalance product structure and gross margins post-centralized procurement [8].

Core Financial Performance - The company reported a revenue of $1.05 billion for the first quarter of fiscal year 2026, representing a year-over-year growth of 2.5% [5] - GAAP net profit was $179 million, a decline of 10.9% compared to the previous year [5] - The gross margin decreased to 60.1%, down approximately 150 basis points year-over-year, primarily due to an increase in tariff-related costs of about $15.3 million [4] - Operating cash flow reached $230 million, showing a year-over-year increase of over 20%, indicating strong cash generation capability [4] Business Structure Analysis - The company remains focused on women's health, but performance varies across different segments: - Diagnostic business saw a revenue decline of 1.3% to $464 million, primarily due to a structural decline following the decrease in COVID-19 testing [6][7] - Breast health revenue was $376 million, reflecting a low single-digit growth driven by products related to Endomagnetics [6][7] - Gynecological surgery revenue reached $181 million, growing by 8.7%, supported by acquisitions and product lines like MyoSure and Fluent [6][7] - Skeletal health revenue was $26.7 million, showing a significant growth of 69%, although it remains a small part of the overall structure [6][7] Corporate Background - The company is headquartered in Massachusetts, USA, and is one of the few medical technology companies that focus systematically on women's health [9] - Its core technologies cover a closed-loop strategy of "diagnostics + intervention + surgery" in women's health, which is a key reason for private equity's willingness to invest at high valuations [9] Special Context of Mergers and Acquisitions - The company is currently in a critical phase of being acquired by Blackstone and TPG private equity firms, with a shareholder special meeting scheduled for February 5, 2026, to vote on the merger agreement [1][2] - Due to the ongoing merger process, all public information is primarily based on established facts rather than future operational forecasts or commitments [12] Conclusion - The company maintains stable cash flow from its core women's health business, and the merger process has entered a definitive shareholder voting stage [14]

Core Viewpoint - Shenzhen Core Medical Technology Co., Ltd. has entered the IPO inquiry stage on the Sci-Tech Innovation Board, marking it as a representative enterprise in the innovative medical device sector [1][2]. Company Overview - Core Medical was established in 2016 and focuses on the research and industrialization of high-end innovative medical devices, particularly artificial hearts and mechanical circulatory support devices [2][5]. - The company aims to raise 1.217 billion yuan, primarily for the development of cutting-edge products, construction of an artificial heart industrialization base, marketing network, and digital system [2]. Financial Performance - Core Medical has not yet achieved profitability, with revenues of 0 yuan in 2022, 16.55 million yuan in 2023, 93.69 million yuan in 2024, and 70.48 million yuan in the first half of 2025. Corresponding net losses were -178 million yuan, -170 million yuan, -132 million yuan, and -72.75 million yuan [3]. - The company has completed six rounds of financing since its inception, with a valuation of approximately 3.545 billion yuan after the D round in April 2025 and around 3.388 billion yuan during a share transfer in August 2025 [2]. Product Matrix - Core Medical has developed a comprehensive product matrix from implantable to interventional systems, including the Corheart® 6, DuoCor®, and CorVad® series, targeting over 60 million heart failure patients globally [5][9]. - The Corheart® 6, an implantable left ventricular assist device, received NMPA approval in June 2023 and is designed for end-stage heart failure patients [12]. Competitive Landscape - Core Medical's products are positioned against competitors like Abbott's HeartMate 3 and other domestic devices, with a focus on innovative features and clinical data supporting their efficacy [12][13][16][20]. - The company is recognized for its advanced technology in miniaturizing artificial hearts, enhancing its competitiveness in the international market [5][7]. Investment and Financing - In April 2025, Core Medical completed a D round financing exceeding 100 million USD, marking one of the largest market-oriented financings in China's innovative medical device sector that year [10]. - The company has received multiple rounds of institutional investment and is supported by recognized professional institutional investors [10]. Regulatory and Market Considerations - As the inquiry phase begins, Core Medical's market valuation, commercial sustainability, and profitability path are expected to be key areas of regulatory focus, providing important reference points for similar innovative medical device companies [3][22].

Group 1 - The core viewpoint of the news is that Dian Diagnostics has seen a stock price increase of 5.31%, reaching 24.41 yuan per share, with a trading volume of 597 million yuan and a turnover rate of 4.98%, resulting in a total market capitalization of 15.256 billion yuan [1] - Dian Diagnostics, established on September 5, 2001, and listed on July 19, 2011, provides medical diagnostic services primarily to various healthcare institutions, with its main business revenue composition being 65.34% from channel products and 34.66% from diagnostic services [1] Group 2 - Among the top ten circulating shareholders of Dian Diagnostics, a fund under Yongying Fund ranks first, while the Medical Device ETF (159883) entered the top ten shareholders in the third quarter, holding 3.0875 million shares, which is 0.62% of the circulating shares, with an estimated floating profit of approximately 3.7976 million yuan [2] - The Medical Device ETF (159883) was established on April 22, 2021, with a current scale of 3.677 billion yuan, showing a year-to-date return of 2.54% and a one-year return of 7.87%, but has experienced a loss of 49.97% since its inception [2]

（原标题：港股异动 | 爱康医疗(01789)涨超4% 计划回购最多1.5亿港元股份 26年已有多个关节机器人中 标待公示） 智通财经APP获悉，爱康医疗(01789)涨超4%，截至发稿，涨2.97%，报5.89港元，成交额925.86万港 元。 fund 消息面上，2月2日，爱康医疗发布公告，董事计划使用股份购回授权，并视乎市况，不时于香港联合交 易所有限公司公开市场使用最多1.5亿港元进行建议股份购回，直至股份购回授权届满日期为止。公司 拟以其内部财务资源为建议股份购回提供资金。公司拟于根据适用规则及法规结算后注销所有购回股 份。 值得一提的是，据爱康医疗官微消息，2026年1月15日，爱康医疗旗下子公司壹点灵动申报的注册项目 关节置换手术导航定位系统(国械注准20263010104)已获得NMPA批准的Ⅲ类医疗器械注册证批件，实现 首个全关节手术机器人，覆盖髋、膝、单髁适应症，并可以进行翻修手术。截至目前，公司累计投放市 场近百台关节机器人产品，形成关节机器人与原有假体业务的有效协同，并且2026年已有多个关节机器 人中标待公示，形成了从医工结合到临床应用的闭环落地。 ...

值得一提的是，据爱康医疗官微消息，2026年1月15日，爱康医疗旗下子公司壹点灵动申报的注册项目 关节置换手术导航定位系统(国械注准20263010104)已获得NMPA批准的Ⅲ类医疗器械注册证批件，实现 首个全关节手术机器人，覆盖髋、膝、单髁适应症，并可以进行翻修手术。截至目前，公司累计投放市 场近百台关节机器人产品，形成关节机器人与原有假体业务的有效协同，并且2026年已有多个关节机器 人中标待公示，形成了从医工结合到临床应用的闭环落地。 消息面上，2月2日，爱康医疗发布公告，董事计划使用股份购回授权，并视乎市况，不时于香港联合交 易所有限公司公开市场使用最多1.5亿港元进行建议股份购回，直至股份购回授权届满日期为止。公司 拟以其内部财务资源为建议股份购回提供资金。公司拟于根据适用规则及法规结算后注销所有购回股 份。 爱康医疗(01789)涨超4%，截至发稿，涨2.97%，报5.89港元，成交额925.86万港元。 ...

Group 1 - The core viewpoint of the news is that the healthcare sector, particularly in A-shares and Hong Kong stocks, is experiencing significant activity and investment interest, driven by AI healthcare and CXO concepts [1][5][6] - The largest healthcare ETF in A-shares (512170) saw a net subscription of 2.633 billion yuan over the past 10 days, indicating strong investor interest [1][6] - The Hong Kong healthcare ETF (159137) rose by 2%, ending a three-day decline, with notable performances from stocks like Ark Health and BeiGene, which increased by over 20% and 4% respectively [1][4] Group 2 - Ark Health raised approximately 144 million HKD through a placement of about 45.181 million shares, with 90% of the funds allocated to accelerate the development of an AI-driven chronic disease management platform [3] - Huawei Cloud launched a dedicated "Smart Healthcare" section aimed at grassroots hospitals, providing AI pathology solutions, in collaboration with Ruijin Hospital [4] - By 2026, AI applications are expected to evolve from usable to highly effective, with a focus on diversified business models in sectors like healthcare, finance, and education [5]